Efficacy and safety of single antiplatelet therapy with anticoagulation in patients with AMI–cardiogenic shock requiring VA-ECMO
Junad M Chowdhury,
Michelle Ferri,
Mary Looby,
Abhimanyu Chandel,
Mehul Desai,
Lauren Albertina,
Michelle Gannon,
Karl D Young,
Evan Franke,
Kimberly Barker,
Lindsay Clevenger,
Thomas Brad Lee,
Benham N. Tehrani,
Ramesh Singh,
Ilan Vavilin,
Mutaz Alkalbani,
Christopher S. King,
Christophe Vandenbriele,
Alexander G. Truesdell,
Division of Medical Critical Care Services,
Department of Medicine,
Inova Fairfax Medical Campus,
Falls Church,
Advanced Lung Disease and Transplant Clinic,
Inova Schar Heart and Vascular,
Falls Church,
Department of Pharmacy,
Inova Fairfax Medical Campus,
Falls Church,
Department of Medicine,
Uniformed Services University of the Health Sciences,
Division of Cardiovascular Critical Care,
Advent Health,
Fl Usa,
Inova Schar Heart and Vascular,
Inova Fairfax Medical Campus,
Falls Church,
Cardiac Intensive Care,
Heart Centrum Aalst,
Intensive Care,
Royal Brompton and Harefield Hospitals,
Guys and St Thomas,
NHS Foundation Trust,
Virginia Heart,
Inova Schar Heart and Vascular,
Falls Church
Perfusion
Published online on June 10, 2026
Perfusion, Ahead of Print.
BackgroundDual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with stenting is standard of care but increases bleeding risk, particularly in patients requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for ...